The added value of a CD4 count to identify patients eligible for highly active antiretroviral therapy among HIV-positive adults in Cambodia

Journal of Acquired Immune Deficiency Syndromes

Volumn 42, Issue 3, 2006, Pages 322-324

  Lynen, Lut ^a   Thai, Sopheak ^b   De Munter, Paul ^b   Leang, Bunse ^b   Sokkab, An ^b   Schrooten, Ward ^c   Huyst, Veerle ^a   Kestens, Luc ^a   Jacques, Gary ^b   Colebunders, Robert ^a,d   Menten, Joris ^a   Van Den Ende, Jef ^a,d  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b Sihanouk Hospital Center of HOPE   (Cambodia)

^c DEPARTMENT OF CARDIOLOGY   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

CD4 count; Clinical criteria; HAART; Total lymphocyte count; WHO

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CAMBODIA; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYMPTOM; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAMBODIA; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; HIV INFECTIONS; HUMANS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 33745903088     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000221682.37316.d5     Document Type: Article

References (19)

1. + T cell count as a tool to monitor HIV progression & anti-retroviral therapy. Indian J Med Res. 2005;121:539-549.
2. Balakrishnan P, Solomon S, Kumarasamy N, et al. Low-cost monitoring of HIV infected individuals on highly active antiretroviral therapy (HAART) in developing countries. Indian J Med Res. 2005;121:345-355.
3. Beck EJ, Kupek EJ, Gompels MM, et al. Correlation between total and CD4 lymphocyte counts in HIV infection: not making the good an enemy of the not so perfect. Int J STD AIDS. 1996;7:422-428.
4. Post FA, Wood R, Maartens G. CD4 and total lymphocyte counts as predictors of HIV disease progression. Q J Med. 1996;89:505-508.
5. Kumarasamy N, Mahajan AP, Flanigan TP, et al. Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries. J Acquir Immune Defic Syndr. 2002;31:378-383.
6. Bedell R, Heath KV, Hogg RS, et al. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings. Antivir Ther. 2003;8:379-384.
7. Spacek LA, Griswold M, Quinn TC, et al. Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings. AIDS. 2003;17:1311-1317.
8. + percentage in a group of HIV-1-infected South African patients. J Acquir Immune Defic Syndr. 1998;19:238-244.
9. Kamya MR, Semitala FC, Quinn TC, et al. Total lymphocyte count of 1200 is not a sensitive predictor of CD4 lymphocyte count among patients with HIV disease in Kampala, Uganda. Afr Health Sci. 2004;4:94-101.
10. Costello C, Nelson KE, Jamieson DJ, et al. Predictors of low CD4 count in resource-limited settings: based on an antiretroviral-naive heterosexual Thai population. J Acquir Immune Defic Syndr. 2005;39:242-248.
11. World Health Organization (WHO). Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2003 revision. Available at: http://www.who.int/hiv/puv_care/en/ arvrerevision2003en.pdf.
12. Teav S, Lynen L, Vereecken C, et al. Alternative CD4 counting using Cyflow in Cambodia: precision and comparison with Facscount [MoPeB3089]. Presented at: XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand.
13. + T lymphocytes in human immunodeficiency virus type 1-infected Thai patients. Clin Diagn Lab Immunol. 2005;12:1416-1424.
14. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17:857-872.
15. Dieye TN, Vereecken C, Diallo AA, et al. Absolute CD4 T-cell counting in resource-poor settings: direct volumetric measurements versus bead-based clinical flow cytometry instruments. J Acquir Immune Defic Syndr. 2005;39:32-37.
16. Saphonn V, Elliott J, Heng S, et al. Estimation of national antiretroviral therapy coverage of medically eligible adults in Cambodia, 1999-2005 [MoPp0303]. Presented at: 3rd IAS Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio de Janeiro, Brazil.
17. Martinson N, Heyer A, Steyn J, et al. Does WHO clinical stage reliably predict who should receive ARV treatment? [WeFo0304]. Presented at: 3rd IAS Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio de Janeiro, Brazil.
18. van der Sande MA, Schim van der Loeff MF, Aveika AA, et al. Body mass index at time of HIV diagnosis: a strong and independent predictor of survival. J Acquir Immune Defic Syndr. 2004;37:1288-1294.
19. Zachariah R, Teck R, Ascurra O, et al. Targeting CD4 testing to a clinical subgroup of patients could limit unnecessary CD4 measurements, premature antiretroviral treatment and costs in Thyolo District, Malawi. Trans R Soc Trop Med Hyg. 2006;100:24-31.